Lattice Radiation Therapy as a Novel Approach for Renal Cell Carcinoma: A Case Series

Spatially fractionated radiation therapy (SFRT) is a treatment modality initially designed for large, deep-seated tumors. Lattice radiation therapy (LRT), a form of SFRT, delivers high and low doses of radiation (RT) in “peaks” and “valleys,” utilizing a three-dimensional pattern while protecting the surrounding organs at risk. We present a case series of two patients with large renal tumors, which were treated with LRT as follows: a 30-year-old male with metastatic renal cell carcinoma (RCC) and a 72-year-old male with RCC and several other comorbidities who completed LRT with minimal toxicity. Both patients received 6670 cGy in 5 fractions delivered twice weekly. These cases support the potential role of LRT in tumor control and symptom palliation. Further research is warranted to delineate the long-term efficacy and toxicity profile of LRT.

Authors

Publication Details

Journal
Cureus
Published
2026-04-16
DOI
https://doi.org/10.7759/cureus.107174
Primary Topic
Renal cell carcinoma treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Lattice Radiation Therapy as a Novel Approach for Renal Cell Carcinoma: A Case Series

Mark K. Buyyounouski, Michael S. Binkley, Jennifer S. Chiang, H.P. Bagshaw et al.
Cureus
Renal cell carcinoma treatment
article

Lattice Radiation Therapy as a Novel Approach for Renal Cell Carcinoma: A Case Series

Mark K. Buyyounouski, Michael S. Binkley, Jennifer S. Chiang, H.P. Bagshaw, Spoorthi Vallamkonda
article en

Abstract

Spatially fractionated radiation therapy (SFRT) is a treatment modality initially designed for large, deep-seated tumors. Lattice radiation therapy (LRT), a form of SFRT, delivers high and low doses of radiation (RT) in “peaks” and “valleys,” utilizing a three-dimensional pattern while protecting the surrounding organs at risk. We present a case series of two patients with large renal tumors, which were treated with LRT as follows: a 30-year-old male with metastatic renal cell carcinoma (RCC) and a 72-year-old male with RCC and several other comorbidities who completed LRT with minimal toxicity. Both patients received 6670 cGy in 5 fractions delivered twice weekly. These cases support the potential role of LRT in tumor control and symptom palliation. Further research is warranted to delineate the long-term efficacy and toxicity profile of LRT.

Cureus
Good health and well-being
Openalex Percentile: Top 6%
Renal cell carcinoma treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.